Scancell
Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist. The key value drivers are iSCIB1+, the lead ImmunoBody programme, and Modi-1, the lead Moditope programme. The novel GlyMab glycan antibodies are earlier in development.

www.scancell.co.uk

Investment Perspective

Scancell is a clinical-stage oncology specialist developing immunotherapies. Its differentiated portfolio is anchored around two novel ‘off-the-shelf’ platforms, ImmunoBody and Moditope, complemented by the GlyMab antibody platform that targets tumour-associated glycans. Collectively, these three platforms offer broad potential across a range of solid tumours. Following FDA sign off on the proposed study design, lead ImmunoBody asset iSCIB1+ is poised to enter a registrational study during 2026, with funding secured through the proposed UK placing, Neuphoria reverse merger and US PIPE transactions. SCOPE Phase II data continues to mature, with further updates expected in H1 calendar 2027. For Moditope, interim data from the renal cell carcinoma (RCC) cohort of the ModiFY study will provide important insights into the potential synergy of lead asset Modi-1 when combined with checkpoint inhibitor therapy. Alongside, the GlyMab portfolio continues to produce compelling preclinical results, with the Genmab partnered assets expected to trigger a near-term development milestone on clinical entry.

Market information

SymbolPrimary exchanges
SCLPAIM London

Research

Atlantic crossing transforms outlook
Update | 06 Oct 2026
Strategic transactions to unlock longer-term value
Lighthouse | 23 Jul 2026
iSCIB1+ pivotal trial plans advancing
Update | 22 Jun 2026

Recent News

Result of General Meeting
20 Oct 2026
FY26 preliminary Results for the year ended 30 April
09 Oct 2026
Publication of Circular, Notice of General Meeting and Proposed Share Consolidation
02 Oct 2026
Completion of up to US$25m in debt financing
24 Sep 2026